PROFESSIONAL EDITION

The largest community of pharma leaders

Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases

SEATTLE–()–Kubota Vision Inc. (“Kubota Vision”), formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the signing of an Open Innovation Agreement with LEO Pharma A/S (“LEO Pharma”) to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds discovered by Kubota Vision. LEO Pharma will evaluate the compounds in disease assays for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis.

During R&D activities to develop novel therapeutics for uveitis, diabetic macular edema, dry eye and post-operative eye inflammation, Kubota Vision discovered several novel VAP-1 inhibitors that are very potent and highly selective. VAP-1 inhibitors, also known as Semicarbazide-Sensitive Amine Oxidase (SSAO) inhibitors, are a promising new class of drugs to treat inflammation-driven diseases. While Kubota Vision has focused on inflammatory eye conditions, VAP-1 inhibitors can potentially be used for multiple inflammatory conditions, including acute respiratory distress syndrome induced by viral infections, such as COVID-19, psoriasis, atopic dermatitis, diabetic kidney disease, osteoarthritis, nonalcoholic steatohepatitis (NASH), certain cancers, and several other diseases.

LEO Pharma established its Open Innovation screening program to collaborate with external partners, including biopharmaceutical companies and academic institutions, to identify promising new therapies for inflammatory skin diseases. As part of this collaborative initiative, LEO Pharma provides in-house expertise and unique research tools to screen promising molecules with potential in the dermatology field. Results of the collaborative science program allow LEO Pharma to engage with partners in an open dialogue regarding potential strategic business partnerships.

For the full text of the press release, please visit here.

Cautionary Statements: https://www.kubotaholdings.co.jp/en/1/index.html

“Kubota Vision”, the Kubota Vision logo and “Kubota” are registered trademarks or trademarks of Kubota Vision Inc. or Kubota Pharmaceutical Holdings in various jurisdictions.

Source

Recent Articles